Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YR 011

Next Previous
Drug Profile

YR 011

Alternative Names: YR-011

Latest Information Update: 22 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator YIRUI Pharmaceutical Technology
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules
  • Mechanism of Action Kv1.3 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis; Inflammatory bowel diseases

Most Recent Events

  • 16 Dec 2025 YIRUI Pharmaceutical Technology plans a phase I trial for Atopic dermatitis, Ulcerative colitis, Chrohn's disease and Psoriasis (In volunteers) in April 2026 (PO, Tablet) (NCT07285967)
  • 31 Jul 2025 YR 011 is available for licensing as of 31 Jul 2025. https://yirui-pharma.com/#pipelines-and-partners-2
  • 31 Jul 2025 Preclinical trials in Atopic dermatitis in China (PO), before July 2025 (Hangzhou Yirui Pharmaceutical Technology pipeline, July 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top